Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Valneva

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the companies.

Euronews

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.

Benzinga

France faces record chikungunya cases as US suspends vaccine licence

Mainland France has recorded an unprecedented rise in chikungunya cases this summer as the tiger mosquito spreads across the country. At the same time, US regulators have suspended the licence of a French-made vaccine after reports of serious side effects.

Radio France Internationale

From analysis to the latest developments in health,
read the most diverse news in one place.

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Valneva SE (NASDAQ:VALN) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.

Benzinga

Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults

Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.

Benzinga

Worst of Westminster: Labour Lords U-turn and interest rates hike

Good evening and welcome to the latest edition of The Worst of Westminster! The week kicked off with MPs voting overwhelmingly to approve the…

The National (Scotland)

Axed Livingston Covid vaccine contract cost taxpayers £358million

The contract was axed by ministers in 2021

Daily Record

Read news from The Economist, FT, and more,
with one subscription

Axed Livingston Covid vaccine contract cost taxpayers £358million

French firm Valneva was supposed to manufacture more than 100 million vaccines at its site in Livingston but the contract was axed by ministers in 2021.

Daily Record

Axed Covid vaccine deal with Livingston firm cost taxpayers £358m

THE UK Government has been accused of “absolutely shafting” a Scottish vaccine plant after it emerged a contract it axed cost taxpayers £358.6…

The National (Scotland)

Axed Covid vaccine contract cost taxpayers £358 million

French company now considering selling the plant specially built in Livingston to manufacture the vaccines

Insider UK

Axed Covid vaccine contract cost taxpayers £358m

The UK Government pulled out of the deal with French firm Valneva in 2021.

The Independent UK

Vaccine trials against chikungunya virus 'promising', but more research is still needed

Franco-Austrian drugmaker Valneva's vaccine candidate against chikungunya – a mosquito-borne virus that causes occasional outbreaks across the world – has revealed promising results in a wide-ranging new trial.

Radio France Internationale

Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket

Gainers

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Reuters

WHO recommends Valneva's COVID vaccine

The World Health Organization (WHO) on Thursday recommended the use of French drugmaker Valneva's COVID-19 vaccine.

WEKU

A vaccine for Lyme disease is in its final clinical trial

There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Axios

Trial seeks to develop first Lyme disease vaccine in 2 decades

The only Lyme disease vaccine previously marketed in the U.S. was discontinued in 2002.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Major test of first possible Lyme vaccine in 20 years begins

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years

Reuters

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Reuters

EU drops nearly all of its order for Valneva COVID vaccine

The European Commission has dropped nearly all of its order of 60 million doses of a new COVID-19 vaccine from French firm Valneva, the EU executive said on Wednesday, in a move that all but wipes out the shot's value for the company. The EU agreed in November last year…

The Independent UK

EU regulator authorizes COVID shot made by France's Valneva

The European Medicines Agency says it is recommending the authorization of the coronavirus vaccine made by French pharmaceutical Valneva, making it the sixth shot to be given the green light in Europe

StockNews.com

Pfizer Strikes Deal With French Vaccine Maker -- Buy Or Sell?

Pharmaceutical company Pfizer (PFE) reported impressive first-quarter financials and is well-positioned to benefit from the equity subscription agreement with French vaccine maker Valneva. However, given the growing economic uncertainty, would it be worth adding the stock to your portfolio? Read more to find out.

Benzinga

Why Shares Of Valneva SE Are Soaring Today

Valneva SE (NASDAQ: VALN) shares are trading higher after the company and Pfizer announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.

1 2 3

People

Mangeet Kaur BounsMangeet

595 stories

Hannah Bardell

49 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.